Table 2.
Endovascular treatment outcomes and grades of hemorrhagic transformation on subsequent imaging.
| Eptifibatide | First control | Second control | P-value | |
|---|---|---|---|---|
| (n = 54) | (n = 54) | (n = 54) | ||
| Number of passes, median (IQR) | 2 (1–2) | 2 (1–3) | 2 (1–3) | 0.79 |
| TICI Score ≥ 2B, no. (%) | 45 (83.3%) | 42 (77.8%) | 42 (77.8%) | 0.70 |
| ICH on follow up imaging, no. (%) | 26 (48.1%) | 27 (50.0%) | 22 (40.7%) | 0.62 |
| ICH grade, no. (%) | ||||
| HI-1 | 5 (9.3%) | 16 (29.6%) | 9 (16.7%) | 0.028 |
| HI-2 | 6 (11.1%) | 4 (7.4%) | 4 (7.4%) | 0.72 |
| PH-1 | 6 (11.1%) | 3 (5.6%) | 1 (1.9%) | 0.15 |
| PH-2 | 9 (16.7%) | 2 (3.7%) | 1 (1.9%) | 0.009 |
| Symptomatic ICH, no. (%) | 3 (5.6%) | 4 (7.4%) | 2(3.7%) | 0.72 |
IQR, interquartile range; TICI, thrombolysis in cerebral infarction; ICH, intracerebral hemorrhage; HI, hemorrhagic infarction; PH, parenchymal hematoma.